Company intelligence / Profile preview

Acurist.AI

California, United States

Ownership: Private
Development stage: Other

Overview

Acurist.AI commercializes a cognitive assessment platform reportedly achieving 97.3% accuracy for memory and cognitive impairment detection; its test is insurer-reimbursed and can be administered via a 10–12 minute video call, helping identify individuals with early cognitive decline and enabling physician decision-support for vascular dementia clinical trials and treatment pathways[4].

Therapeutic areas: Neurology
Modalities: Diagnostics (cognitive diagnostics platform for memory impairment and vascular dementia)Digital health platform
Industry: Digital Health Medical Devices

Partnerships

Hemostemix (revenue-share partnership combining Acurist.AI cognitive diagnostics with Hemostemix’s regenerative therapies for clinical trial patient assessment in vascular dementia)[4]

Beyond the preview

Go deeper on Acurist.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acurist.AI.

Explore the full profile